Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients

ClinicalTrials.gov ID: NCT02152943

Public ClinicalTrials.gov record NCT02152943. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 10, 2026, 2:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Combination Treatment With Everolimus, Letrozole and Trastuzumab in Hormone Receptor and HER2/Neu-Positive Patients With Advanced Metastatic Breast Cancer and Other Solid Tumors: Evaluating Synergy and Overcoming Resistance

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase I trial studies the side effects and best dose of everolimus and trastuzumab when given together with letrozole in treating patients with hormone receptor-positive and human epidermal growth factor (EGF) receptor 2 (HER2)-positive breast cancer or other solid tumors that have spread to other places in the body. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by blocking the use of estrogen by tumor cells. Immunotherapy with monoclonal antibodies, such as trastuzumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving everolimus, letrozole, and trastuzumab together may be a better treatment for breast cancer and other solid tumors than everolimus alone.

Study identification

NCT ID: NCT02152943
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: M.D. Anderson Cancer Center; Other
Enrollment: 37 participants

Conditions and interventions

Conditions

Interventions

Drug · Other · Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 16, 2014
Primary completion: Dec 13, 2020
Completion: Dec 13, 2020
Last update posted: Dec 18, 2020

2014 – 2020

United States locations

U.S. sites: 5
U.S. states: 1
U.S. cities: 4

Facility	City	State	ZIP	Site status
M D Anderson Cancer Center	Houston	Texas	77030	—
MD Anderson in Katy	Houston	Texas	77094	—
MD Anderson League City	Nassau Bay	Texas	77058	—
MD Anderson in Sugar Land	Sugar Land	Texas	77478	—
MD Anderson in The Woodlands	The Woodlands	Texas	77384	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02152943, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 18, 2020 · Synced Sep 10, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02152943 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →